Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia

Free Radical Biology and Medicine

Volumn 40, Issue 10, 2006, Pages 1796-1803

  Bai, Huai ^a   Liu, Bing Wen ^a   Deng, Zu Yue ^a   Shen, Tao ^a   Fang, Ding Zhi ^a   Zhao, Yu Hua ^a   Liu, Yu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Coagulation and fibrinolysis; Endogenous hypertriglyceridemia; Free radicals; HDL; LDL; Oxidative modification; Platelet; VLDL

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; OXIDATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTHROMBIN TIME; RAT; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION;

AGED; ANIMALS; BLOOD COAGULATION; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PROTHROMBIN TIME; RATS; RATS, WISTAR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 33646132025     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.01.007     Document Type: Article

References (47)

1. Malloy M.J., and Kane J.P. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv. Intern. Med. 47 (2001) 111-136
2. Miller G.J. Lipoproteins and thrombosis: effects of lipid lowering. Curr. Opin. Lipidol. 6 (1995) 38-42
3. Sane T., and Nikkila E.A. Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Arteriosclerosis 8 (1988) 217-226
4. Grundy S.M., Mok H.Y.I., Zech L., Steinberg D., and Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J. Clin. Invest. 63 (1979) 1274-1283
5. Breslow J.L., and Dammerman M. Genetic basis of lipoprotein disorders. Circulation 91 (1995) 505-512
6. Liu B.W. Study on lipid and lipoproteins levels in normal subjects and coronary heart disease patients. Natl. Med. J. China 56 (1976) 88-92
7. Yia Herttuala S., Palinski W., Rosenfeld M., Parthasarathy S., Carew T.E., and Butler S. Evidence for the presence of oxidatively modified LDL in atherosclerotic lessions of rabbit and man. J. Clin. Invest. 28 (1989) 1086-1095
8. Weis J.R., Pitas R.E., Wilson B.D., and Rodgers G.M. Oxidized low density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J. 5 (1991) 2459-2465
9. Ishii H., Kizaki K., Horie S., and Kazama M. Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes. J. Biol. Chem. 271 (1996) 8458-8465
10. Horie S., Hiraishi S., Hirata Y., Kazama M., and Matsuda J. Oxidized low-density lipoprotein impairs the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells. Biochem. J. 352 (2000) 277-285
11. Takahashi Y., Chiba H., Matsuno K., Akita H., Hui S.P., Nagasaka H., Nakamura H., Kobayashi K., Tandon N.N., and Jamieson G.A. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem. Biophys. Res. Commun. 15; 222 (1996) 453-459
12. Liu B.W., Jiang Y., Fu M.D., Liu Y., and Fan P. Oxidative modification of lipoproteins in hypertriglyceridemic patients and hypercholesterolemic rabbits in vivo. Mol. Cell. Biochem. 207 (2000) 131-135
13. Schaefer E.J., and Levy R.I. Pathogenesis and management of lipoprotein disorders. N. Engl. J. Med. 312 (1985) 1300-1310
14. Liu B.W. Immunoassays of human plasma apolipoproteins and their clinical applications. In: Wang K.Q. (Ed). Lipoproteins and atherosclerosis (1995), People's Health Press, Beijing 359-368
15. Zhang L.H., and Liu B.W. Separation of human serum lipoproteins by one-step density gradient ultracentrifugation. Acta Biochim. Biophys. Sin. 21 (1989) 257-260
16. Markwell M., Haas S.M., Bieber L.L., and Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87 (1978) 206-210
17. La Ville A.E., Sola R., Balanya J., Turner P.R., and Masana L. In vitro oxidized HDL is recognized by the scavenger receptor of macrophages: implications for its protective role in vivo. Atherosclerosis 105 (1994) 179-189
18. Yan L.J., Lodge J.K., Traber M.G., Matsugo S., and Packer L. Comparison between copper-mediated and hypochlorite-mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation. J. Lipid Res. 38 (1997) 992-1001
19. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free. Radic. Res. Commun. 6 (1989) 67-75
20. Liu R., Saku K., Zhang B., Hirata K., Shiomi M., and Arakawa K. In viro kinetics of oxidatively modified HDL. Biochem. Med. Metab. Biol. 49 (1993) 392-397
21. Noble R.P. Electrophoretic separation of plasma lipoproteins in agarose gel. J. Lipid Res. 9 (1968) 693-700
22. Griffin J.H., Fernandez J.A., and Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb. Haemost. 86 (2001) 386-394
23. Barrowcliffe T.W., Gray E., Kerry P.J., and Gutteridge J.M. Triglyceride-rich lipoproteins are responsible for thrombin generation induced by lipid peroxides. Thromb. Haemost. 31 52 (1984) 7-10
24. Parthasarathy S., Barnett J., and Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta 1044 (1990) 275-283
25. Navab M., Imes S.S., Hama S.Y., Hough G.P., Ross L.A., Bork R.W., Valente A.J., Berliner J.A., Drinkwater D.C., Laks H., and Fogelman A.M. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88 (1991) 2039-2046
26. Griffin J.H., Kojima K., Banka C.L., Curtiss L.K., and Fernandez J.A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103 (1999) 219-227
27. Zago V., Sanguinetti S., Brites F., Berg G., Verona J., Basilio F., Wikinski R., and Schreier L. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 177 (2004) 203-210
28. Allison B.A., Nilsson L., Karpe F., Hamsten A., and Eriksson P. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1354-1360
29. Sundell I.B., Nilsson T.K., Hallmans G., Hellsten G., and Dahlen G.H. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis 80 (1989) 9-16
30. Steele J.C.H., Speidel T.M., and Chandler A.B. The affect of hyperlipoproteinemia on thrombolysis: in vitro studies using purified lipoproteins from nomolipemic donors. Thromb. Res. 43 (1986) 325-334
31. Maruyama I. Coagulation fibrinolytic system and platelet in acute coronary syndrome. Nippon Rinsho 56 (1998) 2488-2492
32. Tremoli E., Camera M., Maderna P., Sironi L., Prati L., Colli S., Piovella F., Bernini F., Corsini A., and Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: an LDL receptor-independent phenomenon. Arterioscler. Thromb. 13 (1993) 338-346
33. Chauton M., Latron Y., Anfosso F., Alessi M.C., Lafont H., Juhan-Vague I., and Nalbone G. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitory secretion induced by oxidized low density lipoproteins in human endothelial cells. J. Lipid. Res. 34 (1993) 101-110
34. Kugiyama K., Sakamoto T., Ohgushi M., Ogawa H., Horiguchi M., and Yasue H. Transferable lipids in oxidized low density lipoprotein stimulate plasminogen activator inhibitory and inhibit tissue plasminogen activator release from endothelial cells. Circ. Res. 73 (1993) 335-343
35. De Castellarnau C., Sanchez-Quesada J.L., Benýtez S., Rosa R., Caveda L., Vila L., and Ordonez-Llanos J. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2281-2287
36. Beaudeux J.L., Therond P., Bonnefont-Rousselot D., Gardes-Albert M., Legrand A., Delattre J., and Peynet J. Comparison of the effects of O2*-/HO* free radical- and copper-oxidized LDL or lipoprotein(a) on the endothelial cell release of tissue plasminogen activator and plasminogen activator inhibitory. Life Sci. 69 (2001) 2371-2382
37. Zhang J.Y., Ren S., Sun D.F., and Shen G.X. Influence of glycation on LDL induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1140-1148
38. Volf I., Roth A., Moeslinger T., Cooper J., Schmid W., Zehetgruber M., and Koller E. Stimulating effect of biologically modified low density lipoproteins on ADP-induced aggregation of washed platelets persists in the absence of specific binding. Thromb. Res. 97 (2000) 441-449
39. Volf I., Moeslinger T., Cooper J., Schmid W., and Koller E. Human platelets exclusively bind oxidized low density lipoprotein showing no specificity for acetylated low density lipoprotein. FEBS Lett. 449 (1999) 141-145
40. Szuwart T., Zhao B., Fritsch A., Mertens K., and Dierichs R. Oxidized low density lipoprotein inhibits the binding of monoclonal antibody to platelet glycoprotein IIB/IIIA. Thromb. Res. 96 (1999) 85-90
41. Zhao B., Dierichs R., Miller F.N., and Dean W.L. Oxidized low density lipoprotein inhibits platelet plasma membrane Ca(2+)-ATPase. Cell Calcium 19 (1996) 453
42. Siess W., Kangl K.G., Essler M., Bauer M., Brandl R., Corrinth C., Bittman R., Tigyi G., and Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 96 (1999) 1636-6931
43. Zhao B., Dierichs R., Liu B., and Holling-Rauss M. Functional morphologic alterations of human blood platelets induced by oxidized low density lipoprotein. Thromb. Res. 74 (1994) 293-301
44. Mahfouz M.M., and Kummerow F.A. Oxysterols and TBARS are among the LDL oxidation products which enhance thromboxane A2 synthesis by platelets. Prostaglandins 56 (1998) 197-217
45. Hackeng C.M., Huigsloot M., Pladet M.W., Nieuwenhuis H.K., van Rijn H.J., and Akkerman J.W. Low density lipoprotein enhances platelet secretion via integrin alphaIIbbeta 3-mediated signaling. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 239-247
46. Pawlowska Z., Swiatkowska M., Krzeslowska J., Pawlicki L., and Ciemiewski C.S. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis 103 (1993) 13-20
47. Gorog P., and Kovacs I.B. Lipid peroxidation by activated platelets: a possible link between thrombosis and atherogenesis. Atherosclerosis 115 (1995) 121-128